Product Code: GVR-2-68038-740-7
Nasal Drug Delivery Technology Market Growth & Trends:
The global nasal drug delivery technology market was valued at USD 127.12 billion in 2022, expanding at a CAGR of 7.45% from 2023 to 2030, according to a new report by Grand View Research, Inc. Growing awareness regarding nasal products is one of the major factors driving the market.
The growing geriatric population is expected to positively drive the overall market. In 2020, there were 727 million people worldwide who are 65 years of age or older, according to a report by the United Nations Department of Economic and Social Affairs. The number of elderly people worldwide is expected to depict more than double growth during the next three decades, reaching over 1.5 billion in 2050. Between 2020 and 2050, the geriatric population is expected to grow in size across the nation. Globally, it is anticipated that the percentage of people 65 and older will rise from 9.3% in 2020 to almost 16.0% in 2050.
Moreover, increasing patient preference for nasal products owing to their efficacy and easy administration is anticipated to fuel the nasal drug delivery systems market growth. For instance, in February 2021, Nanoform Finland and Herantis announced their agreement on nasal drug delivery to the brain by creating a non-exclusive agreement for formulation proof of concept initiatives.
Additionally, the nasal drug delivery method is widely used to treat brain disorders as it offers a route for systemic circulation of drugs, low bioavailability, fast absorption, and desirable action. In this respect, nasal drug delivery could serve as an attractive non-invasive delivery method for CNS drugs. Moreover, nasal delivery of substances such as peptoids, raltitrexed, 5-fluorouracil telomerase inhibitors, and methotrexate has been shown to reduce brain tumors and increase survival in animal models.
Nasal Drug Delivery Technology Market Report Highlights:
- Based on dosage form, the nasal spray segment held the largest revenue share in 2022 owing to the increasing incidence of infections and allergic rhinitis and growing demand for generic nasal spray drugs
- By container type, the non-pressurized containers segment dominated the market in 2022. Nasal drops, nasal powder, and nasal gel usually come in these containers. Growing demand for related products is expected to propel the segment growth over the forecast period
- In terms of therapeutic application, the rhinitis segment held the largest share in 2022 due to the availability of related products for its treatment
- By distribution channel, the retail pharmacies segment accounted for the largest share in 2022 owing to easy availability and convenience
- North America held the largest market share in 2022 owing to the rising prevalence of asthma and chronic obstructive pulmonary disease and the widespread usage of early treatment measures
Table of Contents
Chapter 1. Methodology and Scope
- 1.1 Market Segmentation & Scope
- 1.1.1 Dosage Form
- 1.1.2 Container Type
- 1.1.3 Therapeutic Application
- 1.1.3 Distribution Channel
- 1.1.5 Regional Scope
- 1.1.6 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.3.5.1 Data for primary interviews in North America
- 1.3.5.3 Data for Primary Interviews in Europe
- 1.3.5.4 Data for Primary Interviews in APAC
- 1.3.5.6 Data for Primary Interviews in Latin America
- 1.3.5.8 Data for Primary Interviews in MEA
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis (Model 1)
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.2 Volume Price Analysis (Model 2)
- 1.6.2.1 Approach 2: Volume Price Analysis
- 1.7 List of Secondary Sources
- 1.8 List of Abbreviations
- 1.9 Objectives
- 1.9.1 Objective 1
- 1.9.2 Objective 2
- 1.9.3 Objective 3
- 1.9.4 Objective 4
Chapter 2 Executive Summary
Chapter 3 Nasal Drug Delivery Technology Market Variables, Trends & Scope
- 3.1 Penetration & Growth Prospect Mapping
- 3.2 Market Dynamics
- 3.2.1 Market Drivers Analysis
- 3.2.1.1 Rising patient preference for nasal drug delivery
- 3.2.1.2 Growing incidence of chronic diseases
- 3.2.1.3 Increasing adoption of self-administration practices
- 3.2.1.4 Development of off-patent drugs for respiratory care
- 3.2.2 Market Restraint Analysis
- 3.2.2.1 Complications associated with the overuse of nasal sprays
- 3.2.2.2 Stringent regulatory framework
- 3.3 Nasal Drug Delivery Technology: Market Analysis Tools
- 3.3.1 SWOT Analysis by PESTEL
- 3.3.2 Industry Analysis - Porter's Five Forces
- 3.4 Impact of COVID-19
- 3.4.1 COVID-19 Impact analysis
- 3.4.2 Impact on market players
Chapter 4 Nasal Drug Delivery Technology Market: Segment Analysis, By Dosage Form, 2018 - 2030 (USD Billion)
- 4.1 Definitions and Scope
- 4.2 Dosage Form Market Share Analysis
- 4.3 Segment Dashboard
- 4.4 Nasal Drug Delivery Technology Market by Dosage Form
- 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1 Nasal Spray
- 4.5.1.1 Nasal Spray Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 4.5.2 Nasal Drop
- 4.5.2.1 Nasal Drop Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 4.5.3 Nasal Gel
- 4.5.3.1 Nasal Gel Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 4.5.4 Nasal Powder
- 4.5.4.1 Nasal Powder Market Estimates and Forecast, 2018 - 2030 (USD Billion)
Chapter 5 Nasal Drug Delivery Technology Market: Segment Analysis, By Container Type, 2018 - 2030 (USD Billion)
- 5.1 Definitions and Scope
- 5.2 Container Type Market Share Analysis
- 5.3 Segment Dashboard
- 5.4 Nasal Drug Delivery Technology Market by Container Type
- 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1 Pressurized Containers
- 5.5.1.1 Pressurized Containers Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 5.5.2 Non-pressurized Containers
- 5.5.2.1 Non-pressurized Containers Market Estimates and Forecast, 2018 - 2030 (USD Billion)
Chapter 6 Nasal Drug Delivery Technology Market: Segment Analysis, By Therapeutic Application, 2018 - 2030 (USD Billion)
- 6.1 Definitions and Scope
- 6.2 Therapeutic Application Market Share Analysis
- 6.3 Segment Dashboard
- 6.4 Nasal Drug Delivery Technology Market by Therapeutic Application
- 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1 Nasal Congestion
- 6.5.1.1 Nasal Congestion Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 6.5.2 Rhinitis
- 6.5.2.1 Rhinitis Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 6.5.3 Asthma
- 6.5.3.1 Asthma Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 6.5.4 Others
- 6.5.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)
Chapter 7 Nasal Drug Delivery Technology Market: Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Billion)
- 7.1 Definitions and Scope
- 7.2 Distribution Channel Market Share Analysis
- 7.3 Segment Dashboard
- 7.4 Nasal Drug Delivery Technology Market by Distribution Channel
- 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.5.1 Hospital Pharmacies
- 7.5.1.1 Hospital Pharmacies Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 7.5.2 Retail Pharmacies
- 7.5.2.1 Retail Pharmacies Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 7.5.3 Online Pharmacies
- 7.5.3.1 Asthma Market Estimates and Forecast, 2018 - 2030 (USD Billion)
- 7.5.4 Others
- 7.5.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Billion)
Chapter 8 Nasal Drug Delivery Technology Market: Regional Market Analysis, 2018 - 2030 (USD Billion)
- 8.1 Regional Market Dashboard
- 8.2 Definitions and Scope
- 8.3 Regional Market Share Analysis
- 8.4 North America
- 8.4.1 North America market estimates and forecast, 2018 - 2030
- 8.4.2 U.S.
- 8.4.2.1 U.S. market estimates and forecast, 2018 - 2030
- 8.4.3 Canada
- 8.4.3.1 Canada market estimates and forecast, 2018 - 2030
- 8.5 Europe
- 8.5.1 Europe market estimates and forecast, 2018 - 2030
- 8.5.2 U.K.
- 8.5.2.1 U.K. market estimates and forecast, 2018 - 2030
- 8.5.3 Germany
- 8.5.3.1 Germany market estimates and forecast, 2018 - 2030
- 8.5.4 France
- 8.5.4.1 France market estimates and forecast, 2018 - 2030
- 8.5.5 Italy
- 8.5.5.1 Italy market estimates and forecast, 2018 - 2030
- 8.5.6 Spain
- 8.5.6.1 Spain market estimates and forecast, 2018 - 2030
- 8.5.7 Sweden
- 8.5.7.1 Sweden market estimates and forecast, 2018 - 2030
- 8.5.8 Denmark
- 8.5.8.1 Denmark market estimates and forecast, 2018 - 2030
- 8.5.9 Norway
- 8.5.9.1 Norway market estimates and forecast, 2018 - 2030
- 8.6 Asia Pacific
- 8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030
- 8.6.2 Japan
- 8.6.2.1 Japan market estimates and forecast, 2018 - 2030
- 8.6.3 China
- 8.6.3.1 China market estimates and forecast, 2018 - 2030
- 8.6.4 India
- 8.6.4.1 India market estimates and forecast, 2018 - 2030
- 8.6.5 Australia
- 8.6.5.1 Australia market estimates and forecast, 2018 - 2030
- 8.6.6 South Korea
- 8.6.6.1 South Korea market estimates and forecast, 2018 - 2030
- 8.6.7 Thailand
- 8.6.7.1 Thailand market estimates and forecast, 2018 - 2030
- 8.7 Latin America
- 8.7.1 Latin America market estimates and forecast, 2018 - 2030
- 8.7.2 Mexico
- 8.7.2.1 Mexico market estimates and forecast, 2018 - 2030
- 8.7.3 Brazil
- 8.7.3.1 Brazil market estimates and forecast, 2018 - 2030
- 8.7.4 Argentina
- 8.7.4.1 Argentina market estimates and forecast, 2018 - 2030
- 8.8 Middle East and Africa
- 8.8.1 Middle East and Africa market estimates and forecast, 2018 - 2030
- 8.8.2 South Africa
- 8.8.2.1 South Africa market estimates and forecast, 2018 - 2030
- 8.8.3 Saudi Arabia
- 8.8.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030
- 8.8.4 UAE
- 8.8.4.1 UAE market estimates and forecast, 2018 - 2030
- 8.8.5 Kuwait
- 8.8.5.1 Kuwait market estimates and forecast, 2018 - 2030
Chapter 9 Nasal Drug Delivery Technology Market - Competitive Analysis
- 9.1 Kind of Competition
- 9.2 Concentration of Market Players
- 9.3 Company Market Share Analysis
- 9.4 Categorization based on the Company's Vision
- 9.5 Company Profiles
- 9.5.1 GlaxoSmithKline PLC
- 9.5.1.1 Company overview
- 9.5.1.2 Financial performance
- 9.5.1.3 Product benchmarking
- 9.5.1.4 Strategic initiatives
- 9.5.2 AstraZeneca PLC
- 9.5.2.1 Company overview
- 9.5.2.2 Financial performance
- 9.5.2.3 Product benchmarking
- 9.5.2.4 Strategic initiatives
- 9.5.3 Pfizer, Inc.
- 9.5.3.1 Company overview
- 9.5.3.2 Financial performance
- 9.5.3.3 Productbenchmarking
- 9.5.3.4 Strategic initiatives
- 9.5.4 OptiNose, Inc.
- 9.5.4.1 Company overview
- 9.5.4.2 Financial performance
- 9.5.4.3 Product benchmarking
- 9.5.4.4 Strategic initiatives
- 9.5.5 Becton, Dickinson and Company
- 9.5.5.1 Company overview
- 9.5.5.2 Financial performance
- 9.5.5.3 Product benchmarking
- 9.5.5.4 Strategic initiatives
- 9.5.6 Promius Pharma, LLC
- 9.5.6.1 Company overview
- 9.5.6.2 Financial performance
- 9.5.6.3 Product benchmarking
- 9.5.6.4 Strategic initiatives
- 9.5.7 Cadila Pharmaceuticals Ltd.
- 9.5.7.1 Company overview
- 9.5.7.2 Financial performance
- 9.5.7.3 Product benchmarking
- 9.5.7.4 Strategic initiatives
- 9.5.8 B.F. Ascher & Company, Inc.
- 9.5.8.1 Company overview
- 9.5.8.2 Financial performance
- 9.5.8.3 Product benchmarking
- 9.5.8.4 Strategic initiatives
- 9.5.9 PendoPharm, Inc.
- 9.5.9.1 Company overview
- 9.5.9.2 Financial performance
- 9.5.9.3 Product benchmarking
- 9.5.9.4 Strategic initiatives
- 9.5.10 Douglas Pharmaceuticals Ltd.
- 9.5.10.1 Company overview
- 9.5.10.2 Financial performance
- 9.5.10.3 Product benchmarking
- 9.5.10.4 Strategic initiatives
- 9.5.11 ENT Technologies Pty. Ltd.
- 9.5.11.1 Company overview
- 9.5.11.2 Financial performance
- 9.5.11.3 Product benchmarking
- 9.5.11.4 Strategic initiatives
- 9.5.12 ENT Technologies Pty. Ltd.
- 9.5.12.1 Company overview
- 9.5.12.2 Financial performance
- 9.5.12.3 Product benchmarking
- 9.5.12.4 Strategic initiatives